Safety of agalsidase alfa in patients with Fabry disease under 7 years.
about
Update on role of agalsidase alfa in management of Fabry disease.Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document.Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysis: effectiveness of ERT in different disease stages.Fabry disease in infancy and early childhood: a systematic literature review.Fabry disease in children: agalsidase-beta enzyme replacement therapy.
P2860
Safety of agalsidase alfa in patients with Fabry disease under 7 years.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Safety of agalsidase alfa in patients with Fabry disease under 7 years.
@en
Safety of agalsidase alfa in patients with Fabry disease under 7 years.
@nl
type
label
Safety of agalsidase alfa in patients with Fabry disease under 7 years.
@en
Safety of agalsidase alfa in patients with Fabry disease under 7 years.
@nl
prefLabel
Safety of agalsidase alfa in patients with Fabry disease under 7 years.
@en
Safety of agalsidase alfa in patients with Fabry disease under 7 years.
@nl
P2093
P2860
P1433
P1476
Safety of agalsidase alfa in patients with Fabry disease under 7 years
@en
P2093
P2860
P304
P356
10.1111/J.1651-2227.2010.02101.X
P407
P577
2011-01-12T00:00:00Z